Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that Wild type KRAS, Wild type NRAS status confers therapeutic sensitivity to Panitumumab in patients with Colorectal Adenocarcinoma.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) as monotherapy after failure of fluoropyrimidine, oxaliplatin, and irinotecan containing chemotherapy regimens.